section, you have learned:
You have successfully completed
"Introduction to INTEGRA Meshed Bilayer
Wound Matrix." To continue your review of
all sections in the COURSE click "NEXT",
otherwise click on the below link.
- INTEGRA Meshed Bilayer
Wound Matrix is indicated for the management
of wounds including partial and full-thickness
wounds, pressure ulcers, venous ulcers, diabetic
ulcers, chronic vascular ulcers, surgical
wounds (donor sites/grafts, post-Mohs
surgery, post-laser surgery, podiatric, wound
dehiscence), trauma wounds (abrasions, lacerations,
second-degree burns, and skin tears) and draining
wounds. INTEGRA Meshed Bilayer Wound
Matrix may be used in conjunction with negative
pressure wound therapy. The device is intended
for one-time use.
Meshed Bilayer Wound Matrix is an advanced
wound care device comprised of a porous matrix
of cross-linked bovine tendon collagen and
glycosaminoglycan. The collagen glycosaminoglycan
biodegradable matrix provides a scaffold for
cellular invasion and capillary growth.
The meshed bilayer matrix allows drainage
of wound exudate and provides a flexible adherent
covering for the wound surface.
- The wound is surgically
debrided or excised to viable tissue and INTEGRA
Meshed Bilayer Wound Matrix is applied.
Over the next 2-4 weeks, the matrix is remodeled
as the patient's cells rebuild the damaged
site while simultaneously degrading the collagen-GAG
matrix. For larger wounds, a thin epidermal
autograft 0.004-0.006 inches (0.1016 - 0.1524
millimeters) may be applied. Wound closure
is typically complete in about 30 days.